| The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... Science translational medicine 13 (593), eabf1906, 2021 | 397 | 2021 |
| LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants K Westendorf, S Žentelis, L Wang, D Foster, P Vaillancourt, M Wiggin, ... Cell reports 39 (7), 2022 | 349 | 2022 |
| Probing the folding mechanism of a leucine zipper peptide by stopped-flow circular dichroism spectroscopy JA Zitzewitz, O Bilsel, J Luo, BE Jones, CR Matthews Biochemistry 34 (39), 12812-12819, 1995 | 242 | 1995 |
| Binding of the catabolite repressor protein CcpA to its DNA target is regulated by phosphorylation of its corepressor HPr BE Jones, V Dossonnet, E Kuster, W Hillen, J Deutscher, RE Klevit Journal of Biological Chemistry 272 (42), 26530-26535, 1997 | 182 | 1997 |
| Soluble thrombomodulin protects ischemic kidneys AA Sharfuddin, RM Sandoval, DT Berg, GE McDougal, SB Campos, ... Journal of the American Society of Nephrology 20 (3), 524-534, 2009 | 151 | 2009 |
| LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... BioRxiv, 2020.09. 30.318972, 2020 | 150 | 2020 |
| A reexamination of the folding mechanism of dihydrofolate reductase from Escherichia coli: verification and refinement of a four-channel model PA Jennings, BE Finn, BE Jones, CR Matthews Biochemistry 32 (14), 3783-3789, 1993 | 147 | 1993 |
| Early intermediates in the folding of dihydrofolate reductase from escherichia coli detected by hydrogen exchange and NMR BE Jones, C Robert Matthews Protein science 4 (2), 167-177, 1995 | 109 | 1995 |
| Local and global dynamics during the folding of Escherichia coli dihydrofolate reductase by time-resolved fluorescence spectroscopy BE Jones, JM Beechem, CR Matthews Biochemistry 34 (6), 1867-1877, 1995 | 97 | 1995 |
| A Strategy for Testing the Suitability of Cysteine Replacements in Dihydrofolate Reductase from Escherichia coli M Iwakura, BE Jones, J Luo, CR Matthews The journal of biochemistry 117 (3), 480-488, 1995 | 84 | 1995 |
| Engineering the proteolytic specificity of activated protein C improves its pharmacological properties DT Berg, B Gerlitz, J Shang, T Smith, P Santa, MA Richardson, KD Kurz, ... Proceedings of the National Academy of Sciences 100 (8), 4423-4428, 2003 | 75 | 2003 |
| Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 M Dougan, M Azizad, P Chen, B Feldman, M Frieman, A Igbinadolor, ... MedRxiv, 2022.03. 10.22272100, 2022 | 74 | 2022 |
| Development of nonpolar surfaces in the folding of Escherichia coli dihydrofolate reductase detected by 1-anilinonaphthalene-8-sulfonate binding BE Jones, PA Jennings, RA Pierre, CR Matthews Biochemistry 33 (51), 15250-15258, 1994 | 68 | 1994 |
| RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery ER Zartler, J Hanson, BE Jones, AD Kline, G Martin, H Mo, MJ Shapiro, ... Journal of the American Chemical Society 125 (36), 10941-10946, 2003 | 61 | 2003 |
| Distinct functions of activated protein C differentially attenuate acute kidney injury A Gupta, B Gerlitz, MA Richardson, C Bull, DT Berg, S Syed, EJ Galbreath, ... Journal of the American Society of Nephrology 20 (2), 267-277, 2009 | 58 | 2009 |
| An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential A Datta-Mannan, B Yaden, V Krishnan, BE Jones, JE Croy Journal of Pharmacology and Experimental Therapeutics 344 (3), 616-623, 2013 | 49 | 2013 |
| Anti-myostatin antibodies J Davies, BE Jones, AI Korytko, PJ Mitchell, RC Smith, LM O'bryan, ... US Patent 7,632,499, 2009 | 48 | 2009 |
| Phosphorylation on histidine is accompanied by localized structural changes in the phosphocarrier protein, HPr from Bacillus subtilis BE Jones, P Rajagopal, RE Klevit Protein science 6 (10), 2107-2119, 1997 | 45 | 1997 |
| Protein C derivatives BE Gerlitz, BW Grinnell, BE Jones US Patent 6,630,138, 2003 | 44 | 2003 |
| Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease RJ Benschop, CK Chow, Y Tian, J Nelson, B Barmettler, S Atwell, ... MAbs 11 (6), 1175-1190, 2019 | 32 | 2019 |
Patricia A. JenningsProfessor of Chemistry and Biochemistry, UCSDVerified email at ucsd.edu
